Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Sky One Pays $2.2 Million for Nine New Drugs

publication date: Nov 13, 2008

China Sky One Medical, Inc. (中国天字一号医药公司) has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China Sky One, the nine products are popular in rural areas of China and have received all necessary SFDA approvals. More details...

Stock Symbol: (NSDQ: CSKI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital